Adherium (ADR.AX) Stock Price

Adherium Price

CLOSED
0.07
​
Market closed

Revenue has compounded at 9.8% per year over the past 14 years to 2.10 M AUD. Adherium's net margin stands at -674.2%, up from -1,898.7% several years earlier.

Adherium stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adherium business model & stock analysis

Adherium Ltd. engages in the development, manufacture, and supply of connected medical devices and respiratory medications used by patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-26. The firm is focused on patient medication adherence, remote monitoring and data management solutions for patients, payers and providers. The Company’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients' use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and chronic obstructive pulmonary disease (COPD), and reduces direct and indirect healthcare costs. The Company’s technologies include The Hailie Remote Patient Management (RPM) Solution, The Hailie Sensors and The Hailie Solution. Its Hailie solution is a cloud-based platform, which captures medication use data from Food and Drug Administration (FDA)-cleared Bluetooth enabled sensors, which wrap around patient inhalers and provide real-time feedback to patients via the Hailie application and to their physicians via the Hailie portal.

Frequently asked questions about Adherium

7 analysts currently rate the Adherium stock: 0 recommend buying, 2 holding and 5 selling.

Converted at the current exchange rate, the Adherium share trades at 0.04 EUR (0.07 AUD).

The revenue of Adherium is 2.10 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Adherium is -14.16 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adherium is currently -23.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adherium stock.

The price-to-sales ratio (P/S) of Adherium is currently 157.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adherium stock.

The Eulerpool Quality Score for Adherium is 2/10.

The ISIN of Adherium is AU000000ADR1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Adherium is ADR.AX. The ticker symbol is used to trade Adherium shares on the stock exchange.

Fair ValueTerminal
0.06 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website adherium.com
Country
Australia
Currency
AUD
Initial public offering
Aug 26, 2015
ISIN
AU000000ADR1
Cusip
Q0137R108
Market capitalization
216.37 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-1.09
P/Ee 2028
1.08
P/Se
34.40
EV/EBIT
—
P/B Ratio
33.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1,273.51 %
Last updated Oct 20, 2026, 1:35 PM

Adherium Peer Group

All fundamentals and in-depth analysis of Adherium

Our stock analysis for Adherium stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adherium. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.